LIVIVO - Search results -

Search results

Result 1 - 10 of total 10

Search options

Article ; Online: Exceptional Response to Copanlisib in a Heavily Pretreated Patient With

Spathas, Nikolaos / Economopoulou, Panagiota / Kotsantis, Ioannis / Oikonomopoulos, Nikolaos / Psyrri, Amanda

JCO precision oncology

2022 Volume 4, Page(s) 335–340

Language	English
Publishing date	2022-01-20
Publishing country	United States
Document type	Journal Article
ISSN	2473-4284
ISSN (online)	2473-4284
DOI	10.1200/PO.19.00049
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Potential Ophthalmological Side Effects Induced by Anti-Neoplastic Regimens for the Treatment of Genitourinary Cancers: A Review.

Sakellakis, Minas / Spathas, Nikolaos / Tsaousis, Konstantinos T / Nikitiadis, Emmanouil N / Linardou, Helena / Diakonis, Vasilios F

Cureus

2022 Volume 14, Issue 7, Page(s) e27266

Abstract: The outcomes of patients with genitourinary (GU) cancers have been steadily improving in recent years. Novel therapies have entered our armamentarium, while several other regimens are currently being studied in clinical trials. This recent explosion of ... ...

Abstract	The outcomes of patients with genitourinary (GU) cancers have been steadily improving in recent years. Novel therapies have entered our armamentarium, while several other regimens are currently being studied in clinical trials. This recent explosion of new agents has improved patient survival and the quality of life for patients, but has also significantly increased the frequency of several side effects. The current review will focus on the potential ocular adverse reactions of GU neoplastic treatments. The broad spectrum of manifestations of ocular toxicity underscores the uniqueness and complexity of the anatomic, physiologic, and metabolic features of the human eye. Most side effects are mild in severity and transient, but some can be severe, disabling, and irreversible. Clinicians should be aware of complications that might be vision threatening and impact the patient's quality of life. In this review, we focused on the ocular toxicity of the antineoplastic regimens that are currently used for the treatment of GU, including prostate cancer, bladder cancer, renal cell carcinoma, testicular cancer, pheochromocytoma, adrenocortical carcinoma, and penile cancer.
Language	English
Publishing date	2022-07-26
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2747273-5
ISSN	2168-8184
ISSN	2168-8184
DOI	10.7759/cureus.27266
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The addition of the immunomodulator mifamurtide to adjuvant chemotherapy for early osteosarcoma: a retrospective analysis.

Kokkali, Stefania / Kotsantis, Ioannis / Magou, Elpida / Sophia, Talagani / Kormas, Theodoros / Diakoumis, Giakoumis / Spathas, Nikolaos / Psyrri, Amanda / Ardavanis, Alexandros

Investigational new drugs

2022 Volume 40, Issue 3, Page(s) 668–675

Abstract: Background: Current treatment recommendations for high grade non-metastatic osteosarcoma include perioperative chemotherapy and surgery. Despite this intensive protocol, approximately 40% of patients will relapse. The addition of the immunomodulator ... ...

Abstract	Background: Current treatment recommendations for high grade non-metastatic osteosarcoma include perioperative chemotherapy and surgery. Despite this intensive protocol, approximately 40% of patients will relapse. The addition of the immunomodulator mifamurtide to adjuvant cytotoxic chemotherapy was associated with a significant improvement in 6-year overall survival (OS) in young patients with resectable osteosarcoma, leading to its approval in Europe and other countries. Very limited real-world data are reported on its use. Methods: We retrospectively evaluated data from osteosarcoma patients who received mifamurtide in the adjuvant setting. Data were obtained from medical records in 2 high-volume bone sarcoma centers. The aim of this study was to collect real-world data on mifamurtide safety and efficacy in Greece. Results: We identified 15 patients with completely resected osteosarcoma who received mifamurtide from September 2015 to January 2020. Median age at diagnosis was 24 years old (16-76). Osteosarcoma arose in the lower extremities (n = 12), in the upper extremities (n = 2) or in the ilium (n = 1). The majority of patients (n = 13) received cisplatin/doxorubicin/methotrexate as perioperative chemotherapy and the remaining patients cisplatin/doxorubicin. After a median follow-up of 46.9 months (range, 32.8-61.1), the median recurrence-free survival was 58.7 months (range, 18.5-98.8) and the median OS 64.1 months (range, 25.6-102.6). Except for fever and chills, the only adverse event probably related to mifamurtide was pericarditis (n = 1). Conclusions: Mifamurtide was well tolerated in a Greek osteosarcoma population, including patients older than 30 years. The small sample size and the non-comparative design do not allow drawing conclusions on the drug benefit in terms of survival.
MeSH term(s)	Acetylmuramyl-Alanyl-Isoglutamine/analogs & derivatives ; Adjuvants, Immunologic/therapeutic use ; Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bone Neoplasms/drug therapy ; Bone Neoplasms/pathology ; Chemotherapy, Adjuvant ; Cisplatin/therapeutic use ; Doxorubicin/therapeutic use ; Humans ; Immunologic Factors/therapeutic use ; Neoplasm Recurrence, Local/drug therapy ; Osteosarcoma/drug therapy ; Osteosarcoma/pathology ; Phosphatidylethanolamines ; Retrospective Studies ; Young Adult
Chemical Substances	Adjuvants, Immunologic ; Immunologic Factors ; Phosphatidylethanolamines ; mifamurtide (1LM890Q4FY) ; Acetylmuramyl-Alanyl-Isoglutamine (53678-77-6) ; Doxorubicin (80168379AG) ; Cisplatin (Q20Q21Q62J)
Language	English
Publishing date	2022-03-21
Publishing country	United States
Document type	Journal Article
ZDB-ID	604895-x
ISSN	1573-0646 ; 0167-6997
ISSN (online)	1573-0646
ISSN	0167-6997
DOI	10.1007/s10637-022-01225-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1823: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: a pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology.

Ntellas, Panagiotis / Spathas, Nikolaos / Agelaki, Sofia / Zintzaras, Elias / Saloustros, Emmanouil

Oncotarget

2019 Volume 10, Issue 11, Page(s) 1209–1216

Abstract: Background: Adjuvant chemotherapy has an indisputable value for early breast cancer patients. Anthracycline and taxane-based regimens (TaxAC) have not been proven superior to taxane & cyclophosphamide (TC), a less toxic combination. Our objective was to ...

Abstract	Background: Adjuvant chemotherapy has an indisputable value for early breast cancer patients. Anthracycline and taxane-based regimens (TaxAC) have not been proven superior to taxane & cyclophosphamide (TC), a less toxic combination. Our objective was to estimate the cumulative evidence for non-inferiority of TC against TaxAC, in the adjuvant setting of patients with HER2-negative, breast cancer. Results: Overall, 7,341 patients were included in this analysis. Superiority of TaxAC or non-inferiority of TC was not established either for the overall population (DFS HR, 1.11; 95% CI, 0.95-1.30; Conclusion: Although non-inferiority of TC was not proven, superiority of TaxAC is still questioned. The present analysis narrows the risk of recurrence between the treatment groups. Considering TC has a more favorable safety profile, the question as to which treatment regimen should be preferred under what circumstances, needs to be individualized according to patients' characteristics and desires. Methods: Treatment efficacy data from The ABC trials, the Plan B trial and a trial by the Hellenic Oncology Research group (HORG) were pooled. Disease free survival (DFS) and overall survival (OS) were scrutinized. A HR of 1.18 for TC versus TaxAC was chosen to demonstrate inferiority.
Language	English
Publishing date	2019-02-05
Publishing country	United States
Document type	Journal Article
ZDB-ID	2560162-3
ISSN	1949-2553 ; 1949-2553
ISSN (online)	1949-2553
ISSN	1949-2553
DOI	10.18632/oncotarget.26632
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Incidence of Disease Recurrence in Patients With Colon and Upper Rectum Adenocarcinoma Stage II and III Receiving Adjuvant Capecitabine Monotherapy: Do Number of Chemotherapy Cycles and Relative Dose Intensity of the Drug Play a Role?

Sgouros, Joseph / Gkoura, Stefania / Spathas, Nikolaos / Tzoudas, Fotios / Karampinos, Konstantinos / Miaris, Nikolaos / Visvikis, Anastasios / Dessypris, Nick / Mauri, Davide / Aravantinos, Gerasimos / Theodoropoulos, Ilias / Stamoulis, George / Samantas, Epaminondas

Clinical colorectal cancer

2023 Volume 22, Issue 2, Page(s) 238–244

Abstract: Introduction/background: Adjuvant capecitabine monotherapy is an option for colon and upper rectum adenocarcinoma patients, providing they have stage II disease with an intermediate risk of recurrence, or stage III but they are above 70's or they have ... ...

Abstract	Introduction/background: Adjuvant capecitabine monotherapy is an option for colon and upper rectum adenocarcinoma patients, providing they have stage II disease with an intermediate risk of recurrence, or stage III but they are above 70's or they have comorbidities. We wanted to examine whether the number of chemotherapy cycles and the relative dose intensity (RDI) of capecitabine monotherapy in the adjuvant setting are affecting disease recurrence. Patients and methods: We included patients with completely resected stage II and III colon and upper rectum cancer who received adjuvant capecitabine monotherapy, from 2003 until May 2020. Patients with early relapse, i.e. during chemotherapy or within 6 months after the completion of adjuvant chemotherapy, and those with rectal cancer who received radiotherapy were excluded. Patients were divided into 3 groups based on the number of chemotherapy cycles received and the RDI. Group A included patients with ≤4 cycles of chemotherapy, group B patients with >4 cycles of chemotherapy and RDI ≤80%, and group C patients with >4 cycles of chemotherapy and RDI >80%. Study's endpoint, was recurrence free survival (RFS). Results: Two hundred twenty six patients with stage II and III disease (164 and 62 respectively) were included. Sixteen, 166 and 44 were included in groups A, B and C respectively. After a median follow-up of 41 months, 21 patients (9,3%) had relapsed. Patients belonging to group C were found to have a trend for lower relapse rate compared to patients belonging to group A or group B. Conclusion: Number of adjuvant capecitabine cycles and RDI might play a role in RFS in patients with stage II and III colon and upper rectum adenocarcinoma.
MeSH term(s)	Humans ; Capecitabine ; Fluorouracil ; Incidence ; Rectum/pathology ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Rectal Neoplasms/pathology ; Chemotherapy, Adjuvant/adverse effects ; Colon/pathology ; Recurrence ; Adenocarcinoma/pathology ; Neoplasm Staging
Chemical Substances	Capecitabine (6804DJ8Z9U) ; Fluorouracil (U3P01618RT)
Language	English
Publishing date	2023-03-04
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2112638-0
ISSN	1938-0674 ; 1533-0028
ISSN (online)	1938-0674
ISSN	1533-0028
DOI	10.1016/j.clcc.2023.02.007
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5798: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 435: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma.

Spathas, Nikolaos / Economopoulou, Panagiota / Cheila, Myrto / Kotsantis, Ioannis / Fanouriakis, Antonis / Kassara, Dimitra / Psyrri, Amanda

Frontiers in oncology

2018 Volume 8, Page(s) 409

Abstract: Introduction: ...

Abstract	Introduction:
Language	English
Publishing date	2018-09-26
Publishing country	Switzerland
Document type	Case Reports
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2018.00409
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC).

Economopoulou, Panagiota / Anastasiou, Maria / Papaxoinis, George / Spathas, Nikolaos / Spathis, Aris / Oikonomopoulos, Nikolaos / Kotsantis, Ioannis / Tsavaris, Onoufrios / Gkotzamanidou, Maria / Gavrielatou, Niki / Vagia, Elena / Kyrodimos, Efthymios / Gagari, Eleni / Giotakis, Evangelos / Delides, Alexander / Psyrri, Amanda

Cancers

2021 Volume 13, Issue 2

Language	English
Publishing date	2021-01-14
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers13020286
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Clinical Benefit of Pazopanib in a Patient with Metastatic Chondrosarcoma: A Case Report and Review of the Literature.

Tsavaris, Onoufrios / Economopoulou, Panagiota / Kotsantis, Ioannis / Reppas, Lazaros / Avgerinou, Chrysanthi / Spathas, Nikolaos / Prevezanou, Maria / Psyrri, Amanda

Frontiers in oncology

2018 Volume 8, Page(s) 45

Abstract: Chondrosarcoma is a rare malignancy characterized by the production of cartilage matrix, displaying heterogeneous histopathology and clinical behavior. Due to lack of effective treatment for advanced disease, the clinical management of metastatic ... ...

Abstract	Chondrosarcoma is a rare malignancy characterized by the production of cartilage matrix, displaying heterogeneous histopathology and clinical behavior. Due to lack of effective treatment for advanced disease, the clinical management of metastatic chondrosarcoma is exceptionally challenging. Chondrosarcomas harbor molecular abnormalities, such as overexpression of platelet-derived growth factor receptor (PDGFR)-alpha and PDGFR-beta, which are required for cancer development, progression, and metastasis. Pazopanib is a potent and selective multitargeted tyrosine kinase inhibitor, which co-inhibits stem cell growth factor receptor (c-KIT), fibroblast growth factor receptor (FGFR), PDGFR, and vascular endothelial growth factor receptor (VEGFR) and has demonstrated clinical activity in patients with advanced previously treated soft tissue sarcoma. Herein, we describe the unique case of a patient with metastatic chondrosarcoma who derived clinical benefit from pazopanib after first-line chemotherapy failure.
Language	English
Publishing date	2018-03-01
Publishing country	Switzerland
Document type	Case Reports
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2018.00045
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.

Spathas, Nikolaos / Belia, Marina / Giannikos, Theofanis / Arapaki, Maria / Efstathopoulou, Maria / Tsourouflis, Gerassimos / Gainaru, Gabriella / Asimakopoulos, John / Tsaftaridis, Panayiotis / K Angelopoulou, Maria / Plata, Eleni / Konstantopoulos, Kostas / P Vassilakopoulos, Theodoros

Journal of B.U.ON. : official journal of the Balkan Union of Oncology

2020 Volume 24, Issue 6, Page(s) 2483–2489

Abstract: Purpose: To present our experience on the use of Brentuximab Vedotin (BV) in patients with relapsed/refractory classical Hodgkin Lymphoma (cHL) and severe liver function impairment with marked jaundice.: Methods: Two patients with relapsed/refractory ...

Abstract	Purpose: To present our experience on the use of Brentuximab Vedotin (BV) in patients with relapsed/refractory classical Hodgkin Lymphoma (cHL) and severe liver function impairment with marked jaundice. Methods: Two patients with relapsed/refractory cHL were evaluated. BV was administered in the presence of liver dysfunction and severe jaundice due to liver infiltration by cHL, as confirmed by PET-CT. Complete blood counts, biochemical profile, physical and imaging findings were reviewed to assess BV efficacy and tolerance. Results: Case 1 had stage IVB, mixed cellularity cHL. Following ABVD chemotherapy, the patient experienced a relapse and responded to IGEV (ifosfamide, gemcitabine, vinorelbine, steroids) chemotherapy followed by autologous stem cell transplantation (ASCT). Thereafter, he experienced a second relapse with constitutional symptoms, severe jaundice and pancytopenia. Liver involvement was confirmed by PET-CT. Case 2 was admitted with a very late relapse of cHL. After a single cycle of gemcitabine-vinorelbine chemotherapy, which was not tolerated, the patient developed fever, anemia and jaundice, with laboratory findings indicating bone marrow and liver infiltration. The latter was confirmed by PET-CT. Both patients received BV monotherapy according to its formal indication at the reduced dose of 1.2 mg/kg due to severe liver impairment and experienced a rapid clinical and laboratory improvement. BV was well tolerated and offered a clinical benefit for approximately 4 months. Conclusions: BV was safely administered to patients with relapsed/refractory cHL and severe liver function impairment with marked jaundice due to liver involvement, offering significant clinical improvement and reversal of liver abnormalities. BV may serve as a bridge to further salvage combination chemotherapy or a transplant procedure.
MeSH term(s)	Adult ; Aged ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Brentuximab Vedotin/therapeutic use ; Drug Resistance, Neoplasm/drug effects ; Hodgkin Disease/drug therapy ; Hodgkin Disease/pathology ; Humans ; Liver Diseases/etiology ; Liver Diseases/pathology ; Liver Diseases/prevention & control ; Male ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/pathology ; Prognosis ; Retrospective Studies
Chemical Substances	Antineoplastic Agents, Immunological ; Brentuximab Vedotin (7XL5ISS668)
Language	English
Publishing date	2020-01-25
Publishing country	Greece
Document type	Case Reports ; Journal Article
ZDB-ID	2040386-0
ISSN	2241-6293 ; 1107-0625
ISSN (online)	2241-6293
ISSN	1107-0625
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5438: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy-A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study.

Spathas, Nikolaos / Goussia, Anna C / Koliou, Georgia-Angeliki / Gogas, Helen / Zagouri, Flora / Batistatou, Anna / Charchanti, Antonia V / Papoudou-Bai, Alexandra / Bobos, Mattheos / Chrisafi, Sofia / Chatzopoulos, Kyriakos / Kostopoulos, Ioannis / Koletsa, Triantafyllia / Arapantoni, Petroula / Pectasides, Dimitrios / Galani, Eleni / Koutras, Angelos / Zarkavelis, George / Saloustros, Emmanouil /

Bafaloukos, Dimitrios / Karanikiotis, Charisios / Bompolaki, Iliada / Aravantinos, Gerasimos / Psyrri, Amanda / Razis, Evangelia / Koumarianou, Anna / Res, Eleni / Linardou, Helena / Fountzilas, George

Cancers

2022 Volume 14, Issue 22

Abstract: Tumor-infiltrating lymphocytes (TILs) contribute to breast cancer (BC) prognosis. We investigated the prognostic impact of CD8+ TILs in patients with early breast cancer treated with adjuvant chemotherapy in a large observational clinical trial. Along ... ...

Abstract	Tumor-infiltrating lymphocytes (TILs) contribute to breast cancer (BC) prognosis. We investigated the prognostic impact of CD8+ TILs in patients with early breast cancer treated with adjuvant chemotherapy in a large observational clinical trial. Along with a 10 year follow-up, considering the efficacy and safety, we report the results of the translational part of our study. We examined the patients' tumors for total (t), stromal (s), and intratumoral (i) CD8 lymphocyte density (counts/mm
Language	English
Publishing date	2022-11-16
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers14225635
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito